"B7-H1 Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An inhibitory B7 antigen that contains V-type and C2 type immunoglobulin domains. It has specificity for the T-CELL receptor PROGRAMMED CELL DEATH 1 PROTEIN and provides negative signals that control and inhibit T-cell responses. It is found at higher than normal levels on tumor cells, suggesting its potential role in TUMOR IMMUNE EVASION.
| Descriptor ID |
D060890
|
| MeSH Number(s) |
D12.776.467.150.300 D12.776.543.095.300 D23.050.301.285.400 D23.529.168.300
|
| Concept/Terms |
B7-H1 Antigen- B7-H1 Antigen
- Antigen, B7-H1
- B7 H1 Antigen
- Programmed Cell Death 1 Ligand 1
- B7-H1 Immune Costimulatory Protein
- B7 H1 Immune Costimulatory Protein
- PD-L1 Costimulatory Protein
- Costimulatory Protein, PD-L1
- PD L1 Costimulatory Protein
- Programmed Cell Death 1 Ligand 1 Protein
- CD274 Antigen
- Antigen, CD274
- Antigens, CD274
- CD274 Antigens
- B7H1 Immune Costimulatory Protein
|
Below are MeSH descriptors whose meaning is more general than "B7-H1 Antigen".
Below are MeSH descriptors whose meaning is more specific than "B7-H1 Antigen".
This graph shows the total number of publications written about "B7-H1 Antigen" by people in this website by year, and whether "B7-H1 Antigen" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2013 | 0 | 1 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 0 | 1 |
| 2017 | 2 | 1 | 3 |
| 2018 | 2 | 1 | 3 |
| 2019 | 2 | 3 | 5 |
| 2020 | 1 | 1 | 2 |
| 2021 | 2 | 0 | 2 |
| 2022 | 1 | 3 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "B7-H1 Antigen" by people in Profiles.
-
Combined MEK/PD-L1 Inhibition Alters Peripheral Cytokines and Lymphocyte Populations Correlating with Improved Clinical Outcomes in Advanced Biliary Tract Cancer. Clin Cancer Res. 2022 Oct 03; 28(19):4336-4345.
-
A digital assay for programmed death-ligand 1 (22C3) quantification combined with immune cell recognition algorithms in non-small cell lung cancer. Sci Rep. 2022 06 13; 12(1):9745.
-
Converting Tumoral PD-L1 into a 4-1BB Agonist for Safer and More Effective Cancer Immunotherapy. Cancer Discov. 2022 05 02; 12(5):1184-1186.
-
Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency. Nat Med. 2022 01; 28(1):125-135.
-
Mutant APC promotes tumor immune evasion via PD-L1 in colorectal cancer. Oncogene. 2021 10; 40(41):5984-5992.
-
Alveolar Macrophages Inherently Express Programmed Death-1 Ligand 1 for Optimal Protective Immunity and Tolerance. J Immunol. 2021 07 01; 207(1):110-114.
-
Can We MIRror the Efficacy of Immune Checkpoints With miRNAs? J Thorac Oncol. 2020 11; 15(11):1703-1704.
-
Avelumab as second-line therapy for metastatic, platinum-treated urothelial carcinoma in the phase Ib JAVELIN Solid Tumor study: 2-year updated efficacy and safety analysis. J Immunother Cancer. 2020 10; 8(2).
-
Impact of PD-L1 expression and human papillomavirus status in anti-PD1/PDL1 immunotherapy for head and neck squamous cell carcinoma-Systematic review and meta-analysis. Head Neck. 2020 04; 42(4):774-786.
-
Causative role of PDLIM2 epigenetic repression in lung cancer and therapeutic resistance. Nat Commun. 2019 11 22; 10(1):5324.